Conceptus has reported financial results for the three and six months ended June 30, 2009. Net sales for the second quarter of 2009 were $33 million, an increase of 29%, as compared to net sales of $25.7 million for the second quarter of 2008. The company reported a net loss for the second quarter of 2009, at $0.6 million, or $0.02 per share, compared to a net loss of $2.6m, or $0.08 per share in the same period of 2008.
It also reported a Non-GAAP net income for the second quarter of 2009, at $2.4 million, or $0.08 per diluted share, as compared to non-GAAP net income for the prior year second quarter of $0.2 million, or $0.01 per diluted share.
For the six months ended June 30, 2009, Conceptus reported net sales of $60.2 million, up 29% compared to net sales of $46.8 million for the first six months of 2008. The net loss was $4.9 million, or $0.16 per share, as compared to the net loss of $9.9 million, or $0.33 per share.
Mark Sieczkarek, president and chief executive officer of Conceptus, said: We had a tremendous first half of the year and over-achieved both our sales and earnings guidance. We believe the momentum we are gaining as evidenced by strong physician metrics and increased consumer awareness positions us to have an excellent 2009 despite challenging global economic conditions. Our current market development initiatives aimed at both the physician and the patient remain the driving force to make the Essure procedure the gold standard in permanent birth control.